Expansion of necrotic core and shedding of Mertk receptor in human carotid plaques: A role for oxidized polyunsaturated fatty acids?

Cardiovascular Research

Volumn 97, Issue 1, 2013, Pages 125-133

  Garbin, Ulisse ^a   Baggio, Elda ^b   Stranieri, Chiara ^a   Pasini, Andrea ^a   Manfro, Stefania ^a   Mozzini, Chiara ^a   Vallerio, Paola ^a   Lipari, Giovanni ^b   Merigo, Flavia ^b   Guidi, Giancesare ^b   Cominacini, Luciano ^a   Fratta Pasini, Anna ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

ADAM17; Apoptosis; Efferocytosis; Mertk; Necrotic core

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYOCTADECADIENOIC ACID; HYDROXYTETRAENOIC ACID; ISOPROSTANE DERIVATIVE; MER TYROSINE KINASE RECEPTOR; MESSENGER RNA; ORAL ANTIDIABETIC AGENT; OXIDIZED POLYUNSATURATED FATTY ACID; POLYUNSATURATED FATTY ACID; TISSUE AROUND THE NECROTIC CORE EXTRACT; TISSUE EXTRACT; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG; UNSATURATED FATTY ACID;

ADULT; AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; CAROTID PLAQUE; CELL EXPANSION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; WESTERN BLOTTING;

ADAM PROTEINS; AGED; APOPTOSIS; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CELL LINE; F2-ISOPROSTANES; FATTY ACIDS, UNSATURATED; FEMALE; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LINOLEIC ACIDS, CONJUGATED; MACROPHAGES; MALE; NECROSIS; OXIDATION-REDUCTION; PHAGOCYTOSIS; PLAQUE, ATHEROSCLEROTIC; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RNA INTERFERENCE; TRANSFECTION;

EID: 84871813033     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs301     Document Type: Article

References (42)

1. Seimon T, Tabas I. Mechanisms and consequences of macrophage apoptosis in atherosclerosis. J Lipid Res 2009;50:382-387.
2. Schrijvers DM, De Meyer GR, Herman AG, Martinet W. Phagocytosis in atherosclerosis: molecular mechanisms and implications for plaque progression and stability. Car-diovasc Res 2007;73:470-480. (Pubitemid 46073944)
3. Tabas I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol 2005;25:2255-2264. (Pubitemid 41552640)
4. Virmani R, Burke AP, Kolodgie FD, Farb A. Vulnerable plaque: the pathology of unstable coronary lesions. J Interv Cardiol 2002;15:439-446. (Pubitemid 35387383)
5. Lemke G, Rothlin CV. Immunobiology of the TAM receptors. Nat Rev Immunol 2008; 8:327-336. (Pubitemid 351595219)
6. Thorp E, Tabas I. Mechanisms and consequences of efferocytosis in advanced atherosclerosis. J Leukoc Biol 2009;86:1089-1095.
7. Newton RC, Solomon KA, Covington MB, Decicco CP, Haley PJ, Friedman SM et al. Biology of TACE inhibition. Ann Rheum Dis 2001;60:25-32.
8. Kazeros A, Harvey BG, Carolan BJ, Vanni H, Krause A, Crystal RG. Overexpression of apoptotic cell removal receptor Mertk in alveolar macrophages of cigarette smokers. Am J Respir Cell Mol Biol 2008;39:747-757.
9. Nagata K, Ohashi K, Nakano T, Arita H, Zong C, Hanafusa H et al. Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky and Mer receptor tyrosine kinases. J Biol Chem 1996;271:30022-30027. (Pubitemid 26389640)
10. Stitt TN, Conn G, Goret M, Lai C, Bruno J, Radzlejewski C et al. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro3/Axl family of receptor tyrosine kinases. Cell 1995;80:661-670.
11. Lutgens E, Tjwa M, Garcia de Frutos P, Wijnands E, Beckers L, Dahlback B et al. Genetic loss of Gas6 induces plaque stability in experimental atherosclerosis. J Pathol 2008;216:55-63.
12. Ait-Oufella H, Pouresmail V, Simon T, Blanc-Brude O, Kinugawa K, Merval R et al. Defective Mer receptor tyrosine kinase signaling in bone marrow cells promotes apop-totic cell accumulation and accelerates atherosclerosis. Arterioscler Thromb Vasc Biol 2008;28:1429-1431.
13. Sather S, Kenyon KD, Lefkowitz JB, Liang X, Varnum BC, Henson PM et al. A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood 2007;109:1026-1033. (Pubitemid 46220648)
14. Thorp E, Vaisar T, Subramanian M, Mautner L, Blobel C, Tabas I. Shedding of the MER tyrosine kinase receptor is mediated by Adam17 through a pathway involving reactive oxygen species, protein kinase {delta}, and P38 map kinase. J Biol Chem 2011;286:33335-33344.
15. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF et al. A metallo-proteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997;385:729-733. (Pubitemid 27098094)
16. Executive Committee for the asymptomatic carotid atherosclerosis study. Endarter-ectomy for asymptomatic carotid artery stenosis. JAMA 1995;273:1421-1428.
17. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000;20:1262-1275. (Pubitemid 30262927)
18. Stary HC. Natural history and histological classification of atherosclerotic lesions: an update. Arterioscler Thromb Vasc Biol 2000;20:1177-1178. (Pubitemid 30262913)
19. Shinomiya K, Fukunaga M, Kiyomoto H, Mizushige K, Tsuji T, Noma T et al. A role of oxidative stress-generated eicosanoid in the progression of arteriosclerosis in type 2 diabetes mellitus model rats. Hypertens Res 2002;25:91-98. (Pubitemid 34196301)
20. 2 alpha generation from acute myocardial infarction heart: insight into abrupt reperfusion and oxidant stress. Fatty Acids 2001;64:161-166. (Pubitemid 32896816)
21. Nishibe A, Kijima Y, Fukunaga M, Nishiwaki N, Sakai T, Nakagawa Y et al. Increased isoprostane content in coronary plaques obtained from vulnerable patients. Prosta-glandins Leukot Essent Fatty Acids 2008;78:257-263. (Pubitemid 351794235)
22. Park EK, Jung HS, Yang HI, Yoo MC, Kim C, Kim KS. Optimized THP-1 differentiation is required for the detection of responses to weak stimuli. Inflamm Res 2007;56:45-50. (Pubitemid 46356230)
23. Dusi S, Donini M, Lissandrini D, Mazzi P, Della Bianca V, Rossi F. Mechanisms of expression of NADPH oxidase components in human cultured monocytes: role of cyto-kines and transcriptional regulators involved. Eur J Immunol 2001;31:929-938. (Pubitemid 32237129)
24. Fratta Pasini A, Anselmi M, Garbin U, Franchi E, Stranieri C, Nava MC et al. Enhanced levels of oxidized low-density lipoprotein prime monocytes to cytokine overproduction via upregulation of CD14 and toll-like receptor 4 in unstable angina. Arterioscler Thromb Vasc Biol 2007;27:1991-1997. (Pubitemid 47312309)
25. Bellido-Martin L, García de Frutos P. Vitamin K-dependent actions of Gas6. Vitam Horm 2008;78:185-209.
26. O'Bryan JP, Fridell YW, Koski R, Varnum B, Liu ET. The transforming receptor tyro-sine kinase, Axl, is post-translationally regulated by proteolytic cleavage. J Biol Chem 1995;270:551-557.
27. 2-isoprostanes in human atherosclerotic lesions. J Clin Invest 1997;100:2028-2034. (Pubitemid 27459357)
28. 2- isoprostanes to plaque instability in human carotid atherosclerosis. J Clin Invest 1999;103:421-427. (Pubitemid 29069993)
29. 2-isoprostanes are not just markers of oxidative stress. Free Rad Biol Med 2008;44:247-256.
30. 2 alpha induce ectodomain shedding of CD163 and release of tumor necrosis factor-alpha from human monocytes. Free Radic Biol Med 2005;39:98-107. (Pubitemid 40733120)
31. Huang JS, Ramamurthy SK, Lin X, Le Breton GC. Cell signalling through thromboxane A2 receptors. Cell Signal 2004;16:521-533. (Pubitemid 38125140)
32. Miggin SM, Kinsella BT. Expression and tissue distribution of the mRNAs encoding the human thromboxane A2 receptor (TP) alpha and beta isoforms. Biochim Biophys Acta 1998;1425:543-559. (Pubitemid 28546689)
33. Meja KK, Barnes PJ, Giembycz MA. Characterization of the prostanoid receptor (s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation. Br J Pharmacol 1997;122:149-157. (Pubitemid 27376032)
34. Dogne JM, Hanson J, Pratico D. Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis. Trends Pharmacol Sci 2005;26:639-644. (Pubitemid 41636309)
35. Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ, Cohen RA. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol 2000;20:1724-1728. (Pubitemid 30470586)
36. Worth NF, Berry CL, Thomas AC, Campbell JH. S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits. Atherosclerosis 2005;183:65-73. (Pubitemid 41416823)
37. Bal Dit Sollier C, Crassard I, Simoneau G, Bergmann JF, Bousser MG, Drouet L. Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial throm-bogenesis after repeated administration in patients treated for the prevention of is-chemic stroke. Cerebrovasc Dis 2009;28:505-513.
38. Bousser MG, Amareno P, Chamorro A, Fisher M, Ford I, Fox KM et al. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet 2011;377:2013-2022.
39. Obinata H, Izumi T. G2A as a receptor for oxidized free fatty acids. Prostaglandins Other Lipid Mediat 2009;89:66-72.
40. Rikitake Y, Hirata K, Yamashita T, Iwai K, Kobayashi S, Itoh H et al. Expression of G2A, a receptor for lysophosphatidylcholine, by macrophages in murine, rabbit, and human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2002;22:2049-2053. (Pubitemid 36025213)
41. Hattori K, Ozaki Y, Ismail TF, Okumura M, Naruse H, Kan S et al. Impact of statin therapy on plaque characteristics as assessed by serial OCT, grayscale and integrated backscatter-IVUS. J Am Coll Cardiol 2012;5:169-177.
42. Bass R, Edwards DR. ADAMs and protein disulfide isomerase: the key to regulated cell-surface protein ectodomain shedding? Biochem J 2010;429:e3-e5.